DUBLIN–(BUSINESS WIRE)–The “Generics Market Summary, Competitive Analysis and Forecast, 2017-2026 (Global Almanac)” report has been added to ResearchAndMarkets.com’s offering.
Global Generics industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2017-21, and forecast to 2026). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.
Key Highlights
- For the purposes of this profile, a generic drug is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the ‘generic-eligible’ market, are not included.
- The market value is evaluated at ex-factory prices.
- Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.
- Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.
- Note that any volumes of ‘1’ (one) or 100% are due to rounding as the publisher does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.
- All market data and forecasts are represented in nominal terms (i.e., without adjustment for inflation) and all currency conversions used in the creation of this report have been calculated using constant 2021 annual average exchange rates.
- The global generics market had total revenues of $321.4 billion in 2021, representing a compound annual growth rate (CAGR) of 4.7% between 2016 and 2021.
- Market consumption volume increased with a CAGR of 1.9% between 2016 and 2021, to reach a total of 47.0 % in 2021.
- Over the past five years, the global generics market recorded growth of 5.2%. Growth has primarily been driven by demographic trends.
Scope
- Save time carrying out entry-level research by identifying the size, growth, and leading players in the global generics market
- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the global generics market
- Leading company profiles reveal details of key generics market players’ global operations and financial performance
- Add weight to presentations and pitches by understanding the future growth prospects of the global generics market with five year forecasts by both value and volume
Reasons to Buy
- What was the size of the global generics market by value in 2021?
- What will be the size of the global generics market in 2026?
- What factors are affecting the strength of competition in the global generics market?
- How has the market performed over the last five years?
- How large is the global generics market in relation to its regional counterparts?
Key Topics Covered:
1 EXECUTIVE SUMMARY
2 Introduction
3 Global Generics
4 Macroeconomic Indicators
5 Generics in Asia-Pacific
6 Generics in Europe
7 Macroeconomic Indicators
8 Generics in France
9 Macroeconomic Indicators
10 Generics in Germany
11 Macroeconomic Indicators
12 Generics in Australia
13 Macroeconomic Indicators
14 Generics in Brazil
15 Macroeconomic Indicators
16 Generics in Canada
17 Macroeconomic Indicators
18 Generics in China
19 Macroeconomic Indicators
20 Generics in India
21 Macroeconomic Indicators
22 Generics in Indonesia
23 Macroeconomic Indicators
24 Generics in Italy
25 Macroeconomic Indicators
26 Generics in Japan
27 Macroeconomic Indicators
28 Generics in Mexico
29 Macroeconomic Indicators
30 Generics in The Netherlands
31 Macroeconomic Indicators
32 Generics in North America
33 Generics in Russia
34 Macroeconomic Indicators
35 Generics in Scandinavia
36 Generics in Singapore
37 Macroeconomic Indicators
38 Generics in South Africa
39 Macroeconomic Indicators
40 Generics in South Korea
41 Macroeconomic Indicators
42 Generics in Spain
43 Macroeconomic Indicators
44 Generics in Turkey
45 Macroeconomic Indicators
46 Generics in The United Kingdom
47 Macroeconomic Indicators
48 Generics in The United States
49 Macroeconomic Indicators
50 Company Profiles
51 Appendix
Companies Mentioned
- Sun Pharmaceutical Industries Ltd
- Les Laboratoires Servier
- STADA Arzneimittel AG
- Sanofi SA
- EMS SA
- Eurofarma Laboratorios SA
- Ache Laboratorios Farmaceuticos SA
- Apotex, Inc.
- Grand Pharmaceutical Group Limited
- Lupin Ltd
- Cipla Limited
- PT Kalbe Farma Tbk
- PT Sanbe Farma
- PT Soho Global Health Tbk
- PT Indofarma (Persero), Tbk
- Viatris Inc.
- Daiichi Sankyo Co Ltd
- Sawai Pharmaceutical Co Ltd
- Teva Pharmaceutical Industries Limited
- Aurobindo Pharma Ltd
- Krka, d. d., Novo mesto
- Abbott Laboratories
- Aspen Pharmacare Holdings Ltd
- Adcock Ingram Holdings Ltd
- Yuhan Corp
- Esteve Group
- Deva Holding AS
- Abdi Ibrahim Ilac Sanayi ve Ticaret AS
- Nobelpharma Co Ltd
- Pfizer Inc.
For more information about this report visit https://www.researchandmarkets.com/r/arcdp
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900